Johnson & Johnson (NYSE:JNJ) is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.
The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience. Its medical devices segment supplies surgical products, orthopedics and interventional solutions through well-known businesses including Ethicon and DePuy Synthes, serving hospitals, physicians and health systems with products for surgery, joint reconstruction and cardiovascular care.
Historically, Johnson & Johnson was also a major consumer health products company with brands for over-the-counter medicines, skincare and first aid; many of those consumer health assets were separated into a standalone publicly traded company, Kenvue, in 2023. J&J continues to emphasize innovation and research, investing in drug discovery, clinical development and device technology while collaborating with academic and industry partners to bring new therapies and technologies to market.
Management is led by Chief Executive Officer Joaquin Duato, who assumed the role in early 2022. The company’s global footprint, diversified portfolio and sizable research infrastructure position it as a prominent participant in the healthcare sector, serving patients, clinicians and consumers across multiple geographies and care settings.
